A future approach will determine whether blocking vacuolar pathway or PKC activation could improve the current therapies used in inflammatory pathologies such as asthma or dermatitis, where the induction/recruitment of CD8+ T lymphocytes correlates with chronic phase of disease. The gene discussed is PRRT2; the disease is asthma.